Earnings, Market Activity, Investment Agreements, Study Data, and Product Deployment - Research Reports on Darden, XPO, Mallinckrodt, SJM and Honeywell

NEW YORK, September 17, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Darden Restaurants, Inc. (NYSE: DRI), XPO Logistics, Inc. (NYSE: XPO), Mallinckrodt PLC (NYSE: MNK), St. Jude Medical Inc. (NYSE: STJ) and Honeywell International Inc. (NYSE: HON). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6529-100free.

--
Darden Restaurants, Inc. Research Reports
On September 12, 2014, Darden Restaurants, Inc. (Darden) reported Q1 FY 2015 financial results (period ended August 24, 2014). Sales for the period were $1.60 billion, up 4.2% YoY. The Company attributed the increase in sales to operation of 55 net new restaurants compared to Q1 FY 2014 and same restaurant-sales increases for LongHorn Steakhouse and the Company's Specialty Restaurants, slightly offset by a same-restaurant sales decline for Olive Garden. Net loss from continuing operations was $19.3 million, compared to a net profit from continuing operations of $42.2 million in the prior year period. On an adjusted basis, earnings for Q1 FY 2015 were 32 cents. Looking forward, Darden expects diluted EPS from continuing operations of $1.74 to $1.84 ($2.22 to $2.30 on an adjusted basis) for FY 2015. The Company also declared a quarterly cash dividend of 55 cents per share, payable on November 3, 2014 to shareholders of record at the close of business on October 10, 2014. The full research reports on Darden are available to download free of charge at:

http://www.analystsreview.com/Sep-17-2014/DRI/report.pdf

--
XPO Logistics, Inc. Research Reports
On September 11, 2014, XPO Logistics, Inc. (XPO) announced that the Company has entered into a definitive agreement with PSP Investments; GIC - Singapore's sovereign wealth fund, and Ontario Teachers' Pension Plan to invest a total of $700 million in XPO to accelerate the Company's growth strategy. XPO informed that it intends to use the net proceeds, primarily for unspecified acquisitions. According to XPO, the transaction, which is complete and scheduled to settle on September 17, 2014, provides for the sale of newly issued common stock and preferred stock to the Investors. Concurrently, the Company raised its 2017 financial targets to c.$9 billion of revenue and $575 million in EBITDA, up from previous targets of $7.5 billion and $425 million, respectively. Following the announcement, XPO's stock marked a new 52-week high of $39.28, amidst high trading volumes, on September 12, 2014. The full research reports on XPO are available to download free of charge at:

http://www.analystsreview.com/Sep-17-2014/XPO/report.pdf

--
Mallinckrodt PLC Research Reports
On September 12, 2014, shares in Mallinckrodt PLC (Mallinckrodt) fell 0.68% from its previous day's close to end the trading session at $86.25. The stock opened at $86.32 and fluctuated in the range of $85.12 and $86.83. A total of 1.91 million shares were traded, lower than the 30-day average trading volume of 3.95 million shares. The stock is trading near its 52-week high of $87.15, which it made on September 4, 2014. Year-till-date the stock has returned an impressive 65.04%, significantly outperforming the NYSE Composite, which returned 4.91%, during the same time period. The full research reports on Mallinckrodt are available to download free of charge at:

http://www.analystsreview.com/Sep-17-2014/MNK/report.pdf

--
St. Jude Medical Inc. Research Reports
On September 13, 2014, St. Jude Medical Inc. (SJM) announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN Renal Denervation System for patients with drug-resistant, uncontrolled hypertension. Commenting on the data, Prof. Stephen Worthley of St. Andrew's Hospital in Adelaide, Australia, a principal investigator of the EnligHTN III study, said, "The twelve-month data for EnligHTN III continues to show the benefits of the EnligHTN Renal Denervation System and merits for its potential to change the way hypertension is treated. These data continue to demonstrate that the multi-electrode system from St. Jude Medical provides a safe and effective alternative for patients with drug-resistant and uncontrolled hypertension." The EnligHTN III study is an international, non-randomized clinical trial that followed device performance and assessed outcomes at six centers through twelve months of follow-up for 37 eligible patients. The full research reports on SJM are available to download free of charge at:

http://www.analystsreview.com/Sep-17-2014/STJ/report.pdf

--
Honeywell International Inc. Research Reports
On September 12, 2014, Honeywell International Inc. (Honeywell) announced that its Solstice® Liquid Blowing Agent (LBA), an ultra low-global-warming-potential foam blowing agent, has been used to help insulate a net-zero energy home project at Purdue University. According to Honeywell, the blowing agent, which causes closed-cell spray foam insulation to expand and provides the majority of the foam's excellent insulating properties, was used to retrofit a residential home in West Lafayette, Indiana. Laura Reinhard, Global Business Manager for Honeywell's spray foam business, said "Solstice LBA has 99.9 percent lower global warming potential than traditional hydrofluorocarbon (HFC) foam blowing agents, yet provides higher insulating performance than HFC blowing agents." The full research reports on Honeywell are available to download free of charge at:

http://www.analystsreview.com/Sep-17-2014/HON/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review